Last updated: 2026-10-14 11:56:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
MeiraGTx Holdings plc (MGTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $10.03, with a market capitalisation of $996.93M and a P/E ratio of 12.09. Over the past 52 weeks, its price has ranged from $6.62 to $15.35. This page covers its latest market performance, valuation, price trends and company information.
$996.93M | |
$9.94 | |
$30.23 | |
$3.49 | |
$9.94 | |
268.00 | |
769.65K | |
12.09 | |
$15.35 | |
$6.62 | |
-- | |
-- |
MeiraGTx Holdings plc (MGTX) is trading at $10.03 in pre-market trading as of 2026-10-14 11:43:00, up 0.87% ($0.09) from the previous close of $9.94
Pre-market trading shows how investors are pricing MGTX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, MeiraGTx Holdings plc (MGTX) moved from $10.92 to $10.03, representing a decline of 8.19% ($0.89).
The stock traded between $9.53 and $11.03 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 1.03 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 39.0%
MGTX is currently trading at $10.03, placing it 39.0% of the way from its 52-week low of $6.62 to its 52-week high of $15.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 393 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MeiraGTx Holdings plc (MGTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.